Thermo Fisher Scientific Inc
TMO · NYSE
TMO · NYSE
The supplied consensus is Buy across 21 analysts, but its target statistics cannot be reconciled: it reports a $750 mean while listing both the low and high target at $570, so neither a valid target range nor the least-bullish analyst can be identified. The two named target revisions in the evidence are clustered at $780-$800: Argus Research raised its target to $780 from $560, and Citi raised its target to $800 from $685, making Citi the most bullish of those two. Both cited revisions were upward and dated Oct. 23, immediately before the trading week; no named-firm downward revision is provided. The substantive disagreement is obscured by the inconsistent consensus data, while the cited firm targets are relatively close.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Citi | — | $800 | +12.8% | Oct 23, 2026 | Open the report this row came from | |
| Argus Research | — | $780 | +10.0% | Oct 23, 2026 |
| Weiss Ratings | — | — | — | Jul 14, 2026 | Open the report this row came from |
| Evercore Inc. | — | $570 | -19.6% | Jul 6, 2026 | Open the report this row came from |
